Comparative Pharmacology
Head-to-head clinical analysis: EDECRIN versus TORSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDECRIN versus TORSEMIDE.
EDECRIN vs TORSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Torsemide inhibits the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption, leading to increased urine output and decreased extracellular fluid volume.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
Oral or intravenous: 5-20 mg once daily; may titrate up to 40 mg daily. Usual maintenance: 5-10 mg daily.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 4-8 hours in cirrhosis and with advanced age. In renal failure (CrCl <30 mL/min), half-life may exceed 8 hours.
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Approximately 80% renal (20% unchanged, 60% as metabolites, mainly glucuronide conjugate), 20% biliary/fecal. In renal impairment, clearance is reduced and half-life prolonged.
Category C
Category A/B
Loop Diuretic
Loop Diuretic